Diminished activity-dependent neuroprotective protein (ADNP) contributes to complement gene elevation in Alzheimer's disease

Abstract

Background

Gene dysregulation is one of the key mechanisms that link pathological abnormalities to cognitive impairment in Alzheimer's disease (AD), the most prevalent neurodegenerative disorder. Our transcriptomic analysis of large-scale postmortem AD human prefrontal cortex (PFC) data revealed that complement genes, a key player in modulating tissue homeostasis and immune surveillance, were prominently upregulated.

Objective

The goal of this study is to reveal key transcriptional regulators that contribute to the elevation of complement genes in AD.

Methods

Transcriptomic and epigenomic analyses, molecular, biochemical and immunocytochemical assays, and in vivo gene manipulation, were used.

Results

Our epigenomic analysis identified ADNP (activity-dependent neuroprotective protein), a chromatin regulator strongly linked to intellectual disability, as one of the top-ranking transcription factors regulating complement genes. ADNP and its partner HP1γ (Heterochromatin protein 1) were found to be significantly diminished in postmortem AD human PFC. Reduced Adnp expression was also found in PFC of a familial AD mouse model, 5xFAD. Knockdown of Adnp in mice led to the significantly increased levels of complement genes, reminiscent to complement gene elevation in postmortem AD humans and 5xFAD mice. Furthermore, human induced pluripotent stem cell-derived neuronal cultures from AD patients exhibited astrocyte activation, ADNP/HP1γ reduction, and complement gene increase. Manipulation of ADNP levels led to bidirectional changes in complement gene expression.

Conclusions

These data suggest that the diminished ADNP in AD could lead to chromatin dysregulation because of disrupted transcriptional repression, which contributes to the elevation of complement genes. It provides a novel upstream epigenetic modifier for gene dysregulation in AD.

Keywords

activity-dependent neuroprotective protein ADNP Alzheimer's disease complement genes epigenetics 5xFAD induced pluripotent stem cells

Get full access to this article

View all access options for this article.

References

Gan

Cookson

Petrucelli

, et al. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci 2018; 21: 1300–1309.

Nichols

St-Pierre

Wendeln

, et al. Inflammatory mechanisms in neurodegeneration. J Neurochem 2019; 149: 562–581.

Bai

Wang

, et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression. Neuron 2020; 105: 975–991.e977.

Zhang

Gaiteri

Bodea

, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013; 153: 707–720.

Mathys

Davila-Velderrain

Peng

, et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature 2019; 570: 332–337.

Zhou

Song

Andhey

, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nat Med 2020; 26: 131–142.

Dalakas

Alexopoulos

Spaeth

. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 2020; 16: 601–617.

Stephan

Barres

Stevens

. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci 2012; 35: 369–389.

Tenner

. Complement-mediated events in Alzheimer's disease: mechanisms and potential therapeutic targets. J Immunol 2020; 204: 306–315.

10.

Tenner

Stevens

Woodruff

. New tricks for an ancient system: physiological and pathological roles of complement in the CNS. Mol Immunol 2018; 102: 3–13.

11.

Hong

Beja-Glasser

Nfonoyim

, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016; 352: 712–716.

12.

Dejanovic

Gandham

, et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep 2019; 28: 2111–2123.e2116.

13.

Stessman

Xiong

Coe

, et al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. Nat Genet 2017; 49: 515–526.

14.

Satterstrom

Kosmicki

Wang

, et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell 2020; 180: 568–584.e523.

15.

Fitzgerald

Gerety

Jones

, et al. Large-scale discovery of novel genetic causes of developmental disorders. Nature 2015; 519: 223–228.

16.

McRae

Clayton

Fitzgerald

, et al. Prevalence and architecture of de novo mutations in developmental disorders. Nature 2017; 542: 433–438.

17.

Ostapcuk

Mohn

Carl

, et al. Activity-dependent neuroprotective protein recruits HP1 and CHD4 to control lineage-specifying genes. Nature 2018; 557: 739–743.

18.

Hadar

Kapitansky

Ganaiem

, et al. Introducing ADNP and SIRT1 as new partners regulating microtubules and histone methylation. Mol Psychiatry 2021; 26: 6550–6561.

19.

Oakley

Cole

Logan

, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006; 26: 10129–10140.

20.

Conrow-Graham

Williams

Martin

, et al. A convergent mechanism of high risk factors ADNP and POGZ in neurodevelopmental disorders. Brain 2022; 145: 3250–3263.

21.

Xie

Bailey

Kuleshov

, et al. Gene set knowledge discovery with enrichr. Curr Protoc 2021; 1: e90.

22.

Robinson

Thorvaldsdóttir

Winckler

, et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24–26.

23.

Qin

Wang

, et al. Social deficits in Shank3-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition. Nat Neurosci 2018; 21: 564–575.

24.

Yang

Ren

Zhong

, et al. Histone demethylase PHF2 regulates inflammatory genes in Alzheimer's disease. Mol Psychiatry 2025; 31: 845–859.

25.

Jiang

Xiao

Saleem

, et al. Generation of human induced pluripotent stem cell-derived cortical neurons expressing the six tau isoforms. J Alzheimers Dis 2025; 105: 1341–1354.

26.

Keenan

Torre

Lachmann

, et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res 2019; 47: W212–W224.

27.

Zamostiano

Pinhasov

Gelber

, et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 2001; 276: 708–714.

28.

Cao

Wang

Williams

, et al. Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimer's disease. Sci Adv 2020; 6: eabc8096.

29.

Williams

Cao

Wang

, et al. Inhibition of histone methyltransferase Smyd3 rescues NMDAR and cognitive deficits in a tauopathy mouse model. Nat Commun 2023; 14: 91.

30.

McQuade

Kang

Hasselmann

, et al. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer's disease. Nat Commun 2020; 11: 5370.

31.

Bassil

Shields

Granger

, et al. Improved modeling of human AD with an automated culturing platform for iPSC neurons, astrocytes and microglia. Nat Commun 2021; 12: 5220.

32.

Chambers

Fasano

Papapetrou

, et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009; 27: 275–280.

33.

Nicoleau

Varela

Bonnefond

, et al. Embryonic stem cells neural differentiation qualifies the role of Wnt/β-Catenin signals in human telencephalic specification and regionalization. Stem Cells 2013; 31: 1763–1774.

34.

Puelles

Rubenstein

. Expression patterns of homeobox and other putative regulatory genes in the embryonic mouse forebrain suggest a neuromeric organization. Trends Neurosci 1993; 16: 472–479.

35.

Lai

Kaspar

Gage

, et al. Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci 2003; 6: 21–27.

36.

Lian

Yang

Cole

, et al. NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron 2015; 85: 101–115.

37.

Luchena

Zuazo-Ibarra

Alberdi

, et al. Contribution of neurons and glial cells to complement-mediated synapse removal during development, aging and in Alzheimer's disease. Mediators Inflamm 2018; 2018: 2530414.

38.

Thion

Ginhoux

Garel

. Microglia and early brain development: an intimate journey. Science 2018; 362: 185–189.

39.

Salter

Stevens

. Microglia emerge as central players in brain disease. Nat Med 2017; 23: 1018–1027.

40.

Hacohen-Kleiman

Sragovich

Karmon

, et al. Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome. J Clin Invest 2018; 128: 4956–4969.

41.

Chen

Dent

. Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat Rev Genet 2014; 15: 93–106.

42.

Clapier

Iwasa

Cairns

, et al. Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes. Nat Rev Mol Cell Biol 2017; 18: 407–422.

43.

Kaaij

LJT

Mohn

van der Weide

, et al. The ChAHP complex counteracts chromatin looping at CTCF sites that emerged from SINE expansions in mouse. Cell 2019; 178: 1437–1451.e1414.

44.

Ivashko-Pachima

Hadar

Grigg

, et al. Discovery of autism/intellectual disability somatic mutations in Alzheimer's brains: mutated ADNP cytoskeletal impairments and repair as a case study. Mol Psychiatry 2021; 26: 1619–1633.

45.

Ivashko-Pachima

Gozes

. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy. Prog Mol Biol Transl Sci 2021; 177: 65–90.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.07 MB